Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Net Margin (2016 - 2026)

Myriad Genetics has reported Net Margin over the past 17 years, most recently at 3.77% for Q4 2025.

  • Quarterly Net Margin rose 1641.0% to 3.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 44.38% through Dec 2025, down 2918.0% year-over-year, with the annual reading at 44.38% for FY2025, 2918.0% down from the prior year.
  • Net Margin was 3.77% for Q4 2025 at Myriad Genetics, up from 13.32% in the prior quarter.
  • Over five years, Net Margin peaked at 14.7% in Q3 2021 and troughed at 155.09% in Q2 2025.
  • The 5-year median for Net Margin is 14.6% (2023), against an average of 22.81%.
  • Year-over-year, Net Margin skyrocketed 5707bps in 2021 and then crashed -13774bps in 2025.
  • A 5-year view of Net Margin shows it stood at 4.73% in 2021, then plummeted by -403bps to 23.79% in 2022, then surged by 33bps to 15.87% in 2023, then fell by -27bps to 20.18% in 2024, then soared by 81bps to 3.77% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Net Margin are 3.77% (Q4 2025), 13.32% (Q3 2025), and 155.09% (Q2 2025).